Quibim secures $50 million in Series A funding to enhance its AI-driven medical imaging solutions aimed at improving disease detection and treatment personalization.
Target Information
Quibim, a premier digital health technology firm, specializes in the application of imaging biomarkers for precision medicine. Founded in 2012 as a spinoff from the La Fe Health Research Institute in Valencia, Spain, the company has rapidly expanded its footprint in the healthcare sector. Quibim leverages artificial intelligence (AI) to analyze medical imaging data derived from MRI, CT, and PET scans, aiming to enhance disease detection and treatment personalization.
With a vision of creating comprehensive digital twins for patients, Quibim operates in over 170 institutions worldwide, providing innovative solutions that significantly refine the understanding of health at a tissue level. Their recent regulatory approvals, including FDA clearance for their services in the US, signify a pivotal point for the company as it aims to broaden its impact in the global healthcare market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The digital health industry, particularly in Spain, is experiencing remarkable growth, driven by advancements in AI and imaging technology. The increasing demand for personalized medicine and improved diagnostic accuracy is propelling innovati
Similar Deals
Asabys, Buenavista, GoHub Ventures, UI Investissement, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, individual investors → Quibim
2025
Asabys Partners and Buenavista Equity Partners → Quibim
2025
Asabys
invested in
Quibim
in 2023
in a Series A deal
Disclosed details
Transaction Size: $50M